Swiss National Bank
AXSM icon

Swiss National Bank’s Axsome Therapeutics AXSM Stock Holding History

Swiss National Bank’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.7M Buy
69,100
+200
+0.3% +$34.5K 0.01% 877
2025
Q4 		$12.6M Buy
68,900
+2,100
+3% +$293K 0.01% 849
2025
Q3 		$8.11M Buy
66,800
+1,600
+2% +$180K ﹤0.01% 1070
2025
Q2 		$6.81M Buy
65,200
+4,200
+7% +$445K ﹤0.01% 1119
2025
Q1 		$7.11M Sell
61,000
-400
-0.7% -$45.6K 0.01% 1064
2024
Q4 		$5.2M Buy
61,400
+900
+1% +$82.8K ﹤0.01% 1312
2024
Q3 		$5.44M Hold
60,500
– – ﹤0.01% 1278
2024
Q2 		$4.87M Hold
60,500
– – ﹤0.01% 1300
2024
Q1 		$4.83M Hold
60,500
– – ﹤0.01% 1325
2023
Q4 		$4.82M Sell
60,500
-11,200
-16% -$749K ﹤0.01% 1313
2023
Q3 		$5.01M Sell
71,700
-4,100
-5% -$306K ﹤0.01% 1274
2023
Q2 		$5.45M Buy
75,800
+5,500
+8% +$406K ﹤0.01% 1265
2023
Q1 		$4.34M Sell
70,300
-2,700
-4% -$177K ﹤0.01% 1366
2022
Q4 		$5.63M Buy
73,000
+3,800
+5% +$227K ﹤0.01% 1245
2022
Q3 		$3.09M Buy
69,200
+2,600
+4% +$130K ﹤0.01% 1578
2022
Q2 		$2.55M Buy
66,600
+8,600
+15% +$272K ﹤0.01% 1746
2022
Q1 		$2.4M Buy
58,000
+4,500
+8% +$139K ﹤0.01% 1928
2021
Q4 		$2.02M Hold
53,500
– – ﹤0.01% 2053
2021
Q3 		$1.76M Hold
53,500
– – ﹤0.01% 2134
2021
Q2 		$3.61M Sell
53,500
-10,500
-16% -$630K ﹤0.01% 1722
2021
Q1 		$3.62M Buy
64,000
+800
+1% +$56.3K ﹤0.01% 1657
2020
Q4 		$5.15M Buy
63,200
+200
+0.3% +$15K ﹤0.01% 1358
2020
Q3 		$4.49M Buy
63,000
+1,100
+2% +$85.7K ﹤0.01% 1241
2020
Q2 		$5.09M Buy
61,900
+15,100
+32% +$1.16M ﹤0.01% 1140
2020
Q1 		$2.75M Buy
46,800
+700
+2% +$57K ﹤0.01% 1254
2019
Q4 		$4.76M Buy
46,100
+2,800
+6% +$113K ﹤0.01% 1180
2019
Q3 		$876K Hold
43,300
– – ﹤0.01% 2120
2019
Q2 		$1.11M Buy
+43,300
New +$868K ﹤0.01% 2057

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Swiss National Bank's AXSM Position: Q1 2026 in Review

Swiss National Bank increased its Axsome Therapeutics (AXSM) stake by 0.29% in Q1 2026, buying an estimated $34.5K and bringing the position to 69,100 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #877.

Swiss National Bank first reported a position in AXSM in Q2 2019 and has held it in 28 quarters since. The position peaked at $12.6M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Swiss National Bank held 69,100 shares of Axsome Therapeutics worth $11.7M as of Q1 2026.
  • Swiss National Bank bought 200 Axsome Therapeutics shares in Q1 2026, an estimated $34.5K.
  • Axsome Therapeutics made up 0.01% of Swiss National Bank's portfolio in Q1 2026, its #877 holding.
  • Swiss National Bank first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Swiss National Bank's Axsome Therapeutics position peaked at $12.6M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.